Annovis Bio, Inc. (NYSE:ANVS) received notice from the FDA that a Phase 3 clinical study with buntanetap in early Parkinson’s patients may proceed. The FDA accepted the final protocol and the clinical development...
Precigen (NASDAQ:PGEN) entered into a definitive agreement to sell its wholly-owned non-healthcare subsidiary, Trans Ova Genetics, an animal reproductive technologies company, to URUS, a holding company with cooperative...
The FDA has cleared Titan Pharmaceuticals’ (NASDAQ:TTNP) investigational new drug application for a Phase 1 study of its six-month or longer subdermal formulation of nalmefene, an opioid antagonist, intended for the...
NeuroSense Therapeutics (NASDAQ:NRSN) reported positive results from a biomarker study conducted to evaluate the potential of CogniC, NeuroSense’s combination drug for the treatment of Alzheimer’s disease...
Domain Therapeutics, which operates in France and Canada, obtained a single-digit multimillion-dollar milestone payment from Merck as part of a €240 million collaboration and license partnership signed in 2017. Drug...
Palisade Bio (NASDAQ:PALI) initiated a Phase 3 study evaluating LB1148 to accelerate the return of bowel function in adult patients undergoing gastrointestinal surgery. The first clinical site in the U.S. is now open...
The United States Patent and Trademark Office has issued a new ENDRA Life Sciences (NASDAQ:NDRA) patent to protect its TAEUS’ radiofrequency (RF) applicator for optimizing the delivery of RF energy to tissue. The...
NeuroSense Therapeutics (NASDAQ:NRSN) reported positive results from stage 3 of its biomarker study conducted in collaboration with Massachusetts General Hospital to evaluate PrimeC, NeuroSense’s lead combination...
Closely-held Zucara Therapeutics reported that its Phase 1b proof-of-concept trial demonstrated ZT-01’s ability to restore glucagon release in people with Type 1 diabetes. Data from 18 subjects that completed all three...
The FDA granted orphan drug designation to Hepion Pharmaceuticals’ (NASDAQ:HEPA) drug candidate, rencofilstat, a liver-targeting, orally administered, novel cyclophilin inhibitor, for the treatment of hepatocellular...